Kura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS ... - Nasdaq

Kura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS ... Nasdaq "Our preliminary data suggests tipifarnib has activity in patients with HRAS mutant squamous cell head and neck cancer, who have failed other treatment options, and we believe Foundation Medicine's unique expertise and outreach to physicians treating ... and more »

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tMaA3J
via IFTTT